Cargando…
Loading, please waitCargando…
Loading, please waitCondition Page — Fibromyalgia
Fibromyalgia is a chronic central-pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive symptoms — driven, the current literature argues, by central nervous system pain amplification and neuroinflammation. Mesenchymal stem cell (MSC) therapy for fibromyalgia is investigational: the supporting evidence is mostly preclinical, and no MSC product is approved by any major regulator for this indication. This page explains, honestly, where the science stands, who can be considered, and how we evaluate cases at our COFEPRIS-regulated clinic in Cancún, México.
Fibromyalgia is a chronic, centrally-mediated pain syndrome with no curative therapy and a multifactorial pathophysiology. The evidence for mesenchymal stem cell (MSC) therapy in fibromyalgia is currently preclinical and early-stage — there are no large randomized trials in humans, and no regulator has approved MSC therapy for this indication. At Regeneris, in Cancún, México, we treat MSC therapy for fibromyalgia as investigational, evaluate every case individually under COFEPRIS-regulated supervision, and never quote a price online: candidacy and any plan are confirmed only after a free medical evaluation, with a personalized written quote to follow.
Clinical overview
Fibromyalgia is a chronic condition defined by widespread musculoskeletal pain, fatigue, non-restorative sleep, and cognitive symptoms ("fibro fog"). The 2014 JAMA clinical review by Daniel J. Clauw reframed it as a centralized pain disorder driven by central nervous system pain amplification rather than peripheral tissue damage. It affects roughly 2–8% of the population worldwide, is more common in women, and shares mechanisms with other so-called nociplastic pain syndromes such as chronic fatigue syndrome and irritable bowel syndrome.
Where the research stands
We do not believe in marketing investigational therapy as if it were proven. The evidence for MSC therapy in fibromyalgia is real but limited: a coherent biological rationale, supportive preclinical work in animal models, and a growing literature on MSC immunomodulation in chronic pain — but no large randomized human trials specific to fibromyalgia, and no regulatory approval. The four citations below summarize the published picture. Each was verified against its primary source; we removed any reference that did not pass that check.
Clauw's 2014 JAMA clinical review consolidated the modern understanding of fibromyalgia as a disorder of central nervous system pain amplification, with widespread pain, fatigue, sleep disturbance, and cognitive symptoms. The review frames the condition as biologically driven, not psychogenic, and outlines the current evidence-based multimodal standard of care — the context against which any new investigational therapy, including MSCs, must be judged.
Clauw DJ. Fibromyalgia: A Clinical Review. JAMA. 2014;311(15):1547–1555.
A 2021 review in the International Journal of Molecular Sciences (Siracusa et al.) describes fibromyalgia as a syndrome of chronic musculoskeletal pain with multifactorial mechanisms — central sensitization, inflammatory and oxidative-stress pathways, genetic susceptibility, and endocrine dysfunction — and concludes that effective management requires multidisciplinary programs targeting peripheral, central, cognitive-emotional, and interpersonal contributors. The neuroinflammatory component is the mechanistic rationale most often invoked for testing MSCs in this condition.
Candidate selection
Candidacy is decided by a physician after a full evaluation in Cancún, never assumed from a diagnosis label or a website form. The lists below describe the general framework we use; specifics depend on your history, comorbidities, and current treatment.
Regulatory framework
Regeneris Therapy operates as a physician-led regenerative clinic in Cancún, México under COFEPRIS — the Mexican federal health authority equivalent to the U.S. FDA. That regulatory backbone is the reason we can offer MSC therapy as an investigational adjunctive option for fibromyalgia patients who choose to be evaluated here, while being explicit that no MSC product is approved by COFEPRIS, the FDA, Health Canada, or any other major regulator for fibromyalgia as an indication.
Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, Quintana Roo, México — federally registered and physician-led.
How we work
We do not publish prices for stem cell therapy online. Fibromyalgia is too individual a condition — and MSC therapy too investigational — for a one-size-fits-all package or a price tag on a webpage. Instead, every plan starts with a free medical evaluation in Cancún (in person or by secure video), after which you receive a written, personalized plan and quote you can review on your own time.
A licensed physician reviews your history, symptoms, current treatments, comorbidities, and recent labs or imaging. We confirm whether a fibromyalgia diagnosis is clinically supported and whether MSC therapy is reasonable to consider as an adjunct.
If we believe MSCs may add value, we say so — and we explain the limits of the evidence in plain language. If we believe they are not appropriate for your case (active cancer, uncontrolled immunosuppression, insufficient optimization of standard care), we say that too.
You receive a written plan with the proposed protocol, source and characterization of the cells, what to expect on application day in Cancún, and a personalized quote — never a price taken from a webpage. You decide on your own time.
Realistic expectations
Fibromyalgia symptom courses are heterogeneous, and any conversation that promises uniform improvement should be treated with skepticism. Here is the framing we use with patients in Cancún:
MSC therapy is not a cure for fibromyalgia. No therapy currently is. We talk about possible reduction in symptom burden — not eradication — and only as an adjunct to a full multidisciplinary plan.
FAQ
The questions we hear most from patients exploring stem cell therapy for fibromyalgia at our COFEPRIS-regulated clinic in Cancún, México.
No. Fibromyalgia currently has no curative therapy, and mesenchymal stem cell (MSC) therapy is no exception. The published evidence for MSCs in fibromyalgia is preclinical and early-stage, and no major regulator — COFEPRIS, FDA, Health Canada, EMA — has approved an MSC product for this indication. Any honest conversation frames MSC therapy as investigational, potentially adjunctive, and integrated with the standard multidisciplinary care of fibromyalgia, not as a cure.
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for fibromyalgia is investigational — there are no large randomized human trials specific to this indication, and no MSC product is approved by COFEPRIS, FDA, Health Canada, or the EMA for fibromyalgia. Outcomes vary by patient and protocol. The decision to consider MSC therapy is a medical decision that requires an individualized evaluation with a licensed physician; disclose every medication, supplement, and diagnosis. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, Quintana Roo, México.
Book a free 15-min call with our team.
Send your history, recent labs, and any imaging. A Regeneris physician in Cancún will review your case and tell you honestly — with a written, personalized quote following your free medical evaluation.
An honest framing matters: fibromyalgia is real, biologically driven, and chronic — and it is not the kind of condition for which any single therapy has been shown to be curative. The standard of care, as the 2014 JAMA review concludes, is a multimodal plan combining education, exercise, cognitive-behavioral therapy, and selectively medication (tricyclics, SNRIs, gabapentinoids).
A widely cited Frontiers in Immunology review (Huh, Ji, Chen, 2017) summarizes how bone marrow stromal cells (a class of MSCs) produce analgesic effects in animal models by secreting transforming growth factor beta (TGF-β) and suppressing neuroinflammation in the peripheral and central nervous systems. The mechanism — modulation of microglia, astrocytes, and pro-inflammatory cytokines — overlaps directly with the neuroinflammatory features of fibromyalgia, providing the biological rationale for testing MSCs in this syndrome. The review covers neuropathic, inflammatory, and cancer pain; fibromyalgia per se is not the subject.
A 2023 study in Life Sciences (Mokhemer et al.) tested bone marrow MSCs in a reserpine-induced rat model of fibromyalgia and reported improved behavioural alterations, restored brain monoamines, reduced oxidative-stress markers, and reduced TNF-α, HMGB-1, NLRP3, and caspase-1 levels in the cerebral cortex. The authors propose NLRP3 inflammasome modulation and neurogenesis promotion as candidate mechanisms. This is preclinical work in animals — it does not establish efficacy in humans, and the study itself frames the findings as hypothesis-generating.
A 2025 review in Immunity, Inflammation and Disease (Hetta et al.) surveys the clinical progress of mesenchymal stem cell therapy across rheumatic diseases and includes an explicit section on fibromyalgia. The authors describe FM as a chronic neurologic disease affecting 2–8% of the global population and discuss the therapeutic potential of bone-marrow-derived MSCs through anti-inflammatory and immunomodulatory mechanisms — while making clear that the human clinical evidence remains early-stage and that MSC therapy for fibromyalgia is not yet an approved indication.
Practical reading: MSC therapy for fibromyalgia has a defensible biological rationale and supportive preclinical data, but it is not an established, proven treatment. We will not tell you otherwise. Any plan we propose treats this modality as investigational and is integrated with — not a substitute for — the multidisciplinary standard of care.
If any of the above applies to your case, it does not automatically rule the therapy out — it means the decision belongs with a physician (and, where relevant, your specialist), not a webpage.
MSC products used at Regeneris in Cancún come from COFEPRIS-certified cell-processing laboratories with documented donor screening, sterility, and viability testing — not from informal sources.
Every fibromyalgia case is reviewed and supervised by a licensed Mexican physician at our Cancún clinic. There is no online checkout, no self-administered protocol, and no quote without a medical evaluation.
Choosing a Cancún clinic should never mean choosing a less-regulated one. The COFEPRIS framework is real, public, and verifiable — and it is the floor below which a serious regenerative medicine practice cannot fall.
If you choose to proceed, the protocol is administered in our COFEPRIS-regulated Cancún facility under physician supervision, with structured follow-up to assess response. The plan is integrated with — not a replacement for — the multidisciplinary care of your fibromyalgia.
Some patients report meaningful improvement in pain, fatigue, sleep, or cognitive symptoms; others do not. The evidence base does not yet allow precise prediction of who responds. Your physician will explain the published findings and the uncertainty together.
MSC therapy is layered onto continued standard care — exercise, sleep optimization, cognitive-behavioral therapy, and any prescribed medication. We do not ask patients to stop the multidisciplinary care that is the established standard.
Honest framing is part of the protocol. If at any point you feel a Regeneris physician is overpromising, that is not how we are trained to talk about fibromyalgia — and we want to know.
The strongest body of evidence sits at the mechanism and preclinical level. Reviews such as Huh et al. (Front Immunol, 2017) describe how MSCs can suppress neuroinflammation and modulate pro-inflammatory cytokines in chronic pain models — mechanisms that overlap with the neuroinflammatory features of fibromyalgia. Animal studies, including Mokhemer et al. (Life Sci, 2023) in a reserpine-induced fibromyalgia rat model, report reduced inflammation, restored brain monoamines, and improved behavioural measures. A 2025 review in Immunity, Inflammation and Disease (Hetta et al.) discusses fibromyalgia explicitly within the broader clinical progress of MSC therapy in rheumatic diseases. None of this is a substitute for large randomized human trials — those have not yet been done for fibromyalgia.
Generally, we consider adults with a physician-confirmed fibromyalgia diagnosis (ACR 2016 criteria) who are already engaged with multidisciplinary care, have no active malignancy or uncontrolled immunosuppression, no active infection, and understand the investigational nature of the therapy. Candidacy is decided in a free medical evaluation with a licensed Mexican physician — never by a webpage and never by a salesperson. If your case is not appropriate, we will tell you.
Regeneris is a physician-led regenerative clinic in Cancún, México, operating under COFEPRIS — the Mexican federal health authority equivalent to the U.S. FDA. The clinic holds Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, and our MSC products come from COFEPRIS-certified cell-processing laboratories with documented donor screening and viability testing. Choosing Cancún does not mean choosing a less-regulated environment — it means choosing a country whose federal health authority allows certain regenerative protocols under medical supervision that remain unavailable in the United States.
We do not publish prices for stem cell therapy on this website. Fibromyalgia is too individual a condition — and MSC therapy too investigational — for a single number to be honest. Every patient starts with a free medical evaluation in Cancún, after which we issue a written, personalized quote. You receive it in writing and can review it on your own time before deciding.
No — and we ask you not to. The standard of care for fibromyalgia, as summarized in the 2014 JAMA review by Clauw, is a multidisciplinary plan combining education, exercise, cognitive-behavioral therapy, and selectively chosen medication (such as tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids). MSC therapy is considered only as a potential adjunct, never as a replacement for that plan. Any changes to medication should be made by the prescribing physician, not based on a regenerative therapy.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How COFEPRIS regulates stem cell therapy in México, what 'Aviso Sanitario' actually means, and how our Cancún clinic operates inside that framework.